{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:04:03Z","timestamp":1792692243835,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The cholesterol gallstones diseases (CGD) is highly correlated with metabolic syndrome and type 2 diabetes. The present study aimed to investigate preventive effects of pioglitazone (PIO), an antidiabetic drug, on the CGD in guinea pigs fed with a lithogenic diet (LD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The guinea pigs were fed with the LD for 8\u2009weeks. All guinea pigs were grouped as follows: low fat diet; LD; LD plus PIO (4\u2009mg\/kg); LD plus PIO (8\u2009mg\/kg); LD plus ezetimibe (EZE) (2\u2009mg\/kg). Gallbladder stones were observed using microscopy. The profile of biliary composition, and blood glucose, insulin and lipid were analyzed. The liver or ileum was harvested for determinations of hydroxyl-methyl-glutaryl-CoA reductase (HMGCR), sterol regulatory element-binding proteins 2 (SREBP2), 7\u03b1-hydroxylase (CYP7A1), adenosine triphosphate-binding cassette (ABC) sterol transporters G5 and G8 (ABCG5, ABCG8), bile salt export pump (BSEP), Niemann-Pick C1-Like 1 (NPC1L1) and acetyl-coenzyme A cholesterol acyltransferase (ACAT2) by Western blot. The gallbladders were used for histological examination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The LD successfully induced gallstone. Both pioglitazone and ezetimibe prevented gallstone formation, as well as hepatic and cholecystic damages. Pioglitazone significantly decreased HMGCR and SREBP2, but increased CYP7A1, ABCG5, ABCG8, and BSEP in the liver. Pioglitazone also remarkably decreased NPC1L1 and ACAT2, while increased ABCG5\/8 in the intestine. The beneficial alterations of cholesterol and bile acids in the bile, as well as profile of glucose, insulin and lipid in the blood were found in the guinea pigs treated with pioglitazone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pioglitazone has a noticeable benefit towards the CGD, which is involved in changes of synthesis, transformation, absorption, and transportation of cholesterol.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12944-019-1159-4","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T15:04:53Z","timestamp":1576076693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pioglitazone prevents cholesterol gallstone formation through the regulation of cholesterol homeostasis in guinea pigs with a lithogenic diet"],"prefix":"10.1186","volume":"18","author":[{"given":"Tao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangge","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"key":"1159_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(06)69044-2","volume":"368","author":"P Portincasa","year":"2006","unstructured":"Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230\u20139.","journal-title":"Lancet."},{"issue":"5","key":"1159_CR2","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.25604","volume":"55","author":"P Portincasa","year":"2012","unstructured":"Portincasa P, Wang DQ. Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: where are we for cholesterol gallstone formation? Hepatology. 2012;55(5):1313\u20136.","journal-title":"Hepatology."},{"issue":"7","key":"1159_CR3","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1111\/j.1365-2982.2012.01935.x","volume":"24","author":"B Lavoie","year":"2012","unstructured":"Lavoie B, Nausch B, Zane EA, et al. Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease. Neurogastroenterol Motil. 2012;24(7):e313\u201324.","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"1159_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/j.gastro.2008.12.031","volume":"136","author":"KJ Maurer","year":"2009","unstructured":"Maurer KJ, Carey MC, Fox JG. Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology. 2009;136(2):425\u201340.","journal-title":"Gastroenterology."},{"issue":"7","key":"1159_CR5","doi-asserted-by":"publisher","first-page":"e70657","DOI":"10.1371\/journal.pone.0070657","volume":"8","author":"JJ Fremont-Rahl","year":"2013","unstructured":"Fremont-Rahl JJ, Ge Z, Umana C, et al. An analysis of the role of the indigenous microbiota in cholesterol gallstone pathogenesis. PLoS One. 2013;8(7):e70657.","journal-title":"PLoS One"},{"key":"1159_CR6","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/eurheartj\/ehv108","volume":"36","author":"BK Lauridsen","year":"2015","unstructured":"Lauridsen BK, Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J. 2015;36:1601\u20138.","journal-title":"Eur Heart J"},{"key":"1159_CR7","doi-asserted-by":"publisher","first-page":"18793","DOI":"10.1074\/jbc.M109927200","volume":"277","author":"JJ Repa","year":"2002","unstructured":"Repa JJ, Berge KE, Chris P, Richardson JA, Helen H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277:18793\u2013800.","journal-title":"J Biol Chem"},{"issue":"20","key":"1159_CR8","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.jacc.2013.12.055","volume":"63","author":"S Stefan","year":"2014","unstructured":"Stefan S, Ruth F-S, Nordestgaard BG, Tybj\u00e6rg-Hansen A. The ABCG5\/8 cholesterol transporter and myocardial infarction versus gallstone disease. J Am Coll Cardiol. 2014;63(20):2121\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1159_CR9","doi-asserted-by":"publisher","first-page":"e40992","DOI":"10.1371\/journal.pone.0040992","volume":"7","author":"E Grenier","year":"2012","unstructured":"Grenier E, Garofalo C, Delvin E, Levy E. Modulatory role of PYY in transport and metabolism of cholesterol in intestinal epithelial cells. PLoS One. 2012;7:e40992.","journal-title":"PLoS One"},{"key":"1159_CR10","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1194\/jlr.M047951","volume":"55","author":"I Jahangir","year":"2014","unstructured":"Jahangir I, Mohamed B, Rudel LL, M Mahmood H. Intestine-specific MTP and global ACAT2 deficiency lowers acute cholesterol absorption with chylomicrons and HDLs. J Lipid Res. 2014;55:2261\u201375.","journal-title":"J Lipid Res"},{"key":"1159_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2016.08.017","volume":"66","author":"CD Fuchs","year":"2017","unstructured":"Fuchs CD, Paumgartner G, Wahlstr\u00f6m A, et al. Metabolic preconditioning protects BSEP\/ABCB11\u2212\/\u2212 mice against cholestatic liver injury. J Hepatol. 2017;66:95\u2013101.","journal-title":"J Hepatol"},{"key":"1159_CR12","first-page":"1644","volume":"7","author":"K Jing","year":"2014","unstructured":"Jing K, Bin-Bin L, Shuo-Dong W, Yu W, Qing-Quan J, En-Ling G. Enhancement of interaction of BSEP and HAX-1 on the canalicular membrane of hepatocytes in a mouse model of cholesterol cholelithiasis. Int J Clin Exp Pathol. 2014;7:1644\u201350.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"1159_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ceb.2007.02.004","volume":"19","author":"MT Bengoechea-Alonso","year":"2007","unstructured":"Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol. 2007;19(2):215\u201322.","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"1159_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00018-011-0857-5","volume":"69","author":"L Goedeke","year":"2012","unstructured":"Goedeke L, Fern\u00e1ndezhernando C. Regulation of cholesterol homeostasis. Cell Mol Life Sci. 2012;69(6):915\u201330.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1159_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/JOE-09-0271","volume":"204","author":"C Zhao","year":"2010","unstructured":"Zhao C, Dahlmanwright K. Liver X receptor in cholesterol metabolism. J Endocrinol. 2010;204(3):233\u201340.","journal-title":"J Endocrinol"},{"key":"1159_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.amjcard.2009.03.023","volume":"104","author":"R Spanheimer","year":"2009","unstructured":"Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B, PROactive Investigators. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009;104:234\u20139.","journal-title":"Am J Cardiol"},{"key":"1159_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1463-1326.2007.00715.x","volume":"9","author":"DJ Betteridge","year":"2007","unstructured":"Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab. 2007;9:640\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1159_CR18","first-page":"107","volume":"8","author":"SD Inbaraj","year":"2014","unstructured":"Inbaraj SD, Josephine IG. Comparative study of lipid and glycemic effects of pioglitazone, rosiglitazone with glibenclamide in patients with type 2 diabetes and dyslipidemia. Global J Pharmacol. 2014;8:107\u201313.","journal-title":"Global J Pharmacol"},{"key":"1159_CR19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0022-2275(20)40677-7","volume":"19","author":"MC Carey","year":"1978","unstructured":"Carey MC. Critical tables for calculating the cholesterol saturation of native bile. J Lip Res. 1978;19:945\u201355.","journal-title":"J Lip Res"},{"key":"1159_CR20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/hep.20867","volume":"42","author":"HH Wang","year":"2010","unstructured":"Wang HH, David Q-HW. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. Hepatology. 2010;42:894\u2013904.","journal-title":"Hepatology."},{"key":"1159_CR21","first-page":"90","volume":"2005","author":"QH Wang","year":"1733","unstructured":"Wang QH, Zhang L, Wang HH. High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochim Biophys Acta. 1733;2005:90\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"1159_CR22","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/j.1440-1746.2012.07227.x","volume":"27","author":"K Ja Kyung","year":"2012","unstructured":"Ja Kyung K, Soo Min C, So Hee K, et al. N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice. J Gastroenterol Hepatol. 2012;27:1745\u201351.","journal-title":"J Gastroenterol Hepatol"},{"key":"1159_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejphar.2015.01.038","volume":"751","author":"XY Song","year":"2015","unstructured":"Song XY, Xu S, Hu JF, et al. Piperine prevents cholesterol gallstones formation in mice. Eur J Pharmacol. 2015;751:112\u20137.","journal-title":"Eur J Pharmacol"},{"key":"1159_CR24","first-page":"7475626","volume":"2018","author":"G Wang","year":"2018","unstructured":"Wang G, Han T, Wang S, Chen M, Sun Y, Fu Z. Peroxisome proliferator-activated receptor-\u03b3 prevents cholesterol gallstone formation in C57bl mice by regulating bile acid synthesis and enterohepatic circulation. Biomed Res Int. 2018;2018:7475626.","journal-title":"Biomed Res Int"},{"key":"1159_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.gastro.2017.04.019","volume":"153","author":"LG Dimova","year":"2017","unstructured":"Dimova LG, de Boer JF, Plantinga J, et al. Inhibiting cholesterol absorption during lactation programs future intestinal absorption of cholesterol in adult mice. Gastroenterology. 2017;153:382\u20135.","journal-title":"Gastroenterology."},{"key":"1159_CR26","first-page":"935","volume":"28","author":"Z Silvia","year":"2010","unstructured":"Silvia Z, H\u00e9ctor M, Lorena A, et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int. 2010;28:935\u201347.","journal-title":"Liver Int"},{"key":"1159_CR27","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1021\/bi00135a001","volume":"31","author":"DW Russell","year":"1992","unstructured":"Russell DW, Setchell KD. Bile acid biosynthesis. J Biochem. 1992;31:4737\u2013449.","journal-title":"J Biochem"},{"key":"1159_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tem.2011.10.004","volume":"23","author":"TI Jeon","year":"2012","unstructured":"Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 2012;23:65\u201372.","journal-title":"Trends Endocrinol Metab"},{"key":"1159_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1177\/153537020623100810","volume":"231","author":"A Klopotek","year":"2006","unstructured":"Klopotek A, Hirche F, Eder K. PPAR gamma ligand troglitazone lowers cholesterol synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp Biol Med (Maywood). 2006;231:1365\u201372.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1159_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jphs.2018.09.013","volume":"139","author":"T Han","year":"2019","unstructured":"Han T, Lv Y, Wang S, Hu T, Hong H, Fu Z. PPAR\u03b3 overexpression regulates cholesterol metabolism in human L02 hepatocytes. J Pharmacol Sci. 2019;139:1\u20138.","journal-title":"J Pharmacol Sci"},{"key":"1159_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","volume":"15","author":"H Shapiro","year":"2018","unstructured":"Shapiro H, Kolodziejczyk AA, Halstuch D, Elinav E. Bile acids in glucose metabolism in health and disease. J Exp Med. 2018;15:383\u201396.","journal-title":"J Exp Med"},{"key":"1159_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517\u201326.","journal-title":"Mol Cell"},{"key":"1159_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0378-1119(00)00518-7","volume":"262","author":"JY Chiang","year":"2001","unstructured":"Chiang JY, Kimmel R, Stroup D. Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene. 2001;262:257.","journal-title":"Gene."},{"key":"1159_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1097-2765(01)00164-2","volume":"7","author":"A Chawla","year":"2001","unstructured":"Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161\u201371.","journal-title":"Mol Cell"},{"issue":"5","key":"1159_CR35","doi-asserted-by":"publisher","first-page":"E383","DOI":"10.25011\/cim.v32i5.6927","volume":"32","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Li Y. Liver X receptors as potential therapeutic targets in atherosclerosis. Clin Invest Med. 2009;32(5):E383\u201394.","journal-title":"Clin Invest Med"},{"key":"1159_CR36","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1194\/jlr.M300182-JLR200","volume":"44","author":"X Guorong","year":"2003","unstructured":"Guorong X, Hai L, Lu-Xing P, et al. FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits. J Lip Res. 2003;44:1956\u201362.","journal-title":"J Lip Res."},{"key":"1159_CR37","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/nm1138","volume":"10","author":"A Moschetta","year":"2004","unstructured":"Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10:1352\u20138.","journal-title":"Nat Med"},{"key":"1159_CR38","doi-asserted-by":"publisher","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","volume":"296","author":"A Mencarelli","year":"2009","unstructured":"Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009;296:H272\u20138.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1159_CR39","doi-asserted-by":"publisher","first-page":"36759","DOI":"10.1074\/jbc.M110.166231","volume":"285","author":"A Mouaadh","year":"2010","unstructured":"Mouaadh A, Sandrine C, Christian D, et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt\/beta-catenin pathways. J Biol Chem. 2010;285:36759\u201367.","journal-title":"J Biol Chem"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-019-1159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-019-1159-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-019-1159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T17:39:14Z","timestamp":1613065154000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-019-1159-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1186\/s12944-019-1159-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animals used in this study were treated strictly according to the National Institutes of Health Guidelines of the Care and Use of Laboratory Animals. All procedures were approved by the Animal Care Review Committee, China Pharmaceutical University, China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}